At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SNDX Syndax Pharmaceuticals
Market Closed 02-14 16:00:00 EST
14.92
-0.16
-1.06%
盘后14.92
+0.000.00%
17:01 EST
High15.40Low14.80Vol1.30M
Open15.19D1 Closing15.08Amplitude3.98%
Mkt Cap1.27BTradable Cap1.18BTotal Shares85.36M
T/O19.57MT/O Rate1.65%Tradable Shares79.18M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Syndax Pharmaceuticals Inc : Guggenheim Cuts Target Price to $32 From $35
THOMSON REUTERS  ·  02-13
Syndax Pharmaceuticals Inc : Guggenheim Cuts Target Price to $32 From $35
Top Executives Make Significant Moves with Syndax Pharmaceuticals Stock!
TIPRANKS  ·  02-13
Top Executives Make Significant Moves with Syndax Pharmaceuticals Stock!
Syndax Pharmaceuticals Up Over 9%, on Pace for Largest Percent Increase Since December 2022 -- Data Talk
Dow Jones  ·  02-07
Syndax Pharmaceuticals Up Over 9%, on Pace for Largest Percent Increase Since December 2022 -- Data Talk
Barclays Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
TIPRANKS  ·  02-06
Barclays Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire  ·  02-05
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Stifel Nicolaus Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)
TIPRANKS  ·  01-31
Stifel Nicolaus Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)
Syndax Announces Participation in February Investor Conferences
PR Newswire  ·  01-30
Syndax Announces Participation in February Investor Conferences
Promising 2025 Outlook for Syndax Pharmaceuticals: Strategic Product Launches and Expansion Plans Drive Buy Recommendation
TIPRANKS  ·  01-23
Promising 2025 Outlook for Syndax Pharmaceuticals: Strategic Product Launches and Expansion Plans Drive Buy Recommendation
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Blockhead  ·  01-17
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
MT Newswires Live  ·  01-16
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease
MT Newswires Live  ·  01-16
Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes
Dow Jones  ·  01-16
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes
Incyte, Syndax announce FDA approval for Niktimvo vial sizes
TIPRANKS  ·  01-16
Incyte, Syndax announce FDA approval for Niktimvo vial sizes
BRIEF-Incyte And Syndax Announce U.S. Food And Drug Administration (FDA) Approval Of Niktimvo™ (Axatilimab-Csfr) 9 mg And 22 mg Vial Sizes
Reuters  ·  01-16
BRIEF-Incyte And Syndax Announce U.S. Food And Drug Administration (FDA) Approval Of Niktimvo™ (Axatilimab-Csfr) 9 mg And 22 mg Vial Sizes
Incyte Corp - Niktimvo Expected to Be Available in U.S. in Early February
THOMSON REUTERS  ·  01-16
Incyte Corp - Niktimvo Expected to Be Available in U.S. in Early February
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (Axatilimab-Csfr) 9 Mg and 22 Mg Vial Sizes
THOMSON REUTERS  ·  01-16
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (Axatilimab-Csfr) 9 Mg and 22 Mg Vial Sizes
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
PR Newswire  ·  01-16
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Syndax Pharmaceuticals (SNDX) Gets a Buy from Bank of America Securities
TIPRANKS  ·  01-15
Syndax Pharmaceuticals (SNDX) Gets a Buy from Bank of America Securities
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire  ·  01-13
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain
Simply Wall St.  ·  01-10
Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain

Introduction

Company Name.
Syndax Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Issue price:
--